Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.74 |
| ▸ | RAB9A | P51151 | 9/20 | 0.68 |
| ▸ | NPC1 | O15118 | 8/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.68 |
| ▸ | MITF | O75030 | 1/20 | 0.67 |
| ▸ | XBP1 | P17861 | 1/20 | 0.67 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.67 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.67 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.65 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.65 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.65 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.65 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.65 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.65 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27866684 | 0.88 | NPC1 (0.80) | KDRRAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL846477 | 0.87 | KDR (0.59) | KDRRAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL23880568 | 0.87 | KDR (0.70) | KDRRAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL995474 | 0.85 | KDR (1.00) | KDRRAB9ANPC1SMN1; SMN2MAPT | |
| SCHEMBL879571 | 0.85 | KDM4E (0.70) | KDRRAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL14461305 | 0.85 | HDAC1 (0.72) | KDRRAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL3994400 | 0.85 | NPSR1 (0.71) | KDRRAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL27617535 | 0.85 | KDR (0.68) | KDRRAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL9132010 | 0.83 | KDR (0.61) | KDRRAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL846245 | 0.83 | TRPV1 (0.56) | KDRRAB9ANPC1SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1659146-A | Process for the manufacture of quinoline derivatives | ACTIVE BIOTECH AB (SE) | 2005-08-24 | — | — | CN | claimed |
| CN-110603253-B | Heteroaryl phenylamino quinolines and analogs | 拜耳公司 | 2023-01-20 | — | — | CN | disclosed |
| CN-109705037-A | 4- aminoquinoline -3- carbamate derivatives and its preparation method and application | 广西师范大学 | 2019-05-03 | — | — | CN | disclosed |
| CN-109705037-A | 4- aminoquinoline -3- carbamate derivatives and its preparation method and application | 广西师范大学 | 2019-05-03 | — | — | CN | disclosed |
| US-8119808-B2 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-21 | — | — | US | disclosed |
| US-8063084-B2 | Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels | NOVARTIS AG (CH) | 2011-11-22 | — | — | US | disclosed |
| US-20110104315-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-05 | — | — | US | disclosed |
| US-7884113-B2 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-08 | — | — | US | disclosed |
| US-20100233116-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2010-09-16 | — | — | US | disclosed |
| US-7709647-B2 | Tetrahydroquinoline cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-04 | — | — | US | disclosed |
| US-20060160850-A1 | Bicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-20 | — | — | US | disclosed |
| EP-1644335-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2006-04-12 | — | — | EP | disclosed |
| CN-1659146-A | Process for the manufacture of quinoline derivatives | ACTIVE BIOTECH AB (SE) | 2005-08-24 | — | — | CN | disclosed |
| WO-2005007628-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20050014786-A1 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2005-01-20 | — | — | US | disclosed |
| US-6602883-B1 | Inhibitors of farnesyl protein transferase | BRISTOL-MYERS SQUIBB COMPANY | 2003-08-05 | — | — | US | disclosed |
| US-6387926-B1 | ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2002-05-14 | — | — | US | disclosed |
| EP-0994856-A4 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL MYERS SQUIBB CO (US) | 2000-12-06 | — | — | EP | disclosed |
| EP-0994856-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-04-26 | — | — | EP | disclosed |
| WO-1999001434-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100233116-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | KDR 3789/4885RAB9A 3869/4885NPC1 242/4885 |
| US-20110104315-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | CNR2, CNR1, OPRL1 | KDR 2855/4885RAB9A 1371/4885NPC1 1136/4885 |
| US-20050014786-A1 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | CNR2, CNR1, OPRL1 | KDR 2855/4885RAB9A 1371/4885NPC1 1136/4885 |
| US-20060160850-A1 | Bicyclic heterocycles as cannabinoid receptor modulators | CNR1, CNR2, GPR18 | KDR 1119/4885RAB9A 1262/4885NPC1 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.